Today’s NYT article on Pradaxa is a textbook case of bias stemming from asymmetric information:
Given that there is indisputably one real meaningful problem and a second highly probable problem I would suggest it isn't very textbook. This is not to say that the problem you mention isn't real in the sense that it will exaggerate the SAE.
Dew, partially true. With coumadin the options of Vit K and fresh frozen plasma remain viable treatment options to reverse adverse bleeding. With Pradaxa the only treatment option so far is "tincture of time" (and a drug with a much shorter half life.) What really is important is what you don't see and that is a substantial reduction in thromboembolic events. Regards, bp
Market Data 
Markets 
AI
